

Posting Date: October 21, 2024

Closing Date: October 30, 2024 11:30 a.m. ET

Reference Number: 25-000308

To: NCI Bid Board

From: Christine Buntz
NCI CCR P-ARC
christine.buntz@nih.gov

Subject: NCI Bid Board Posting - Service Agreement for the Benchmark Ultra for the Laboratory of Pathology.

The National Cancer Institute Division of The Laboratory of Pathology at the National Cancer Institute (NCI) is an integral component of the research and clinical community at the National Institutes of Health (NIH). Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education.

The primary objective of the service agreement is to guarantee timely maintenance and repair service for the Benchmark Ultra that guarantees 24-hour emergency support and repair service that uses OEM parts. This service is required through the manufacturer of said equipment for continued service to our facility to maintain the highest level of accuracy and equipment performance. This is necessary to provide the highest quality immunohistochemistry testing for the benefit of NCI/NIH patients enrolled in clinical protocols without risk of equipment failure.

The National Cancer Institute plans to purchase a service agreement for Benchmark XT from Roche Diagnostics Corporation, Indianapolis, IN to perform this work. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine if the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on October 30, 2024, ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

Roche Diagnostics Corporation is the sole manufacturer of the Benchmark XT, and Roche Diagnostics Corporation requires their personnel to maintain their instruments for continued use as they are the manufacturer of this equipment. Market research was conducted, and vendors were contacted, however there are no other companies that are able to meet the requirement. Original manufacturer service is required to avoid nullifying the warranty. Any equipment failure would adversely affect NCI/NIH clinical center patients and their optimal care.

Attached Documents:

SF18

Statement of Work

FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request.